| Reticulocytosis | |
| Width: | 133px |
| Field: | Hematology |
Reticulocytosis is a laboratory finding in which the number of reticulocytes (immature red blood cells) in the bloodstream is elevated. Reticulocytes account for approximately 0.5% to 2.5% of the total red blood cells in healthy adults and 2% to 6% in infants, but in reticulocytosis, this percentage rises.[1] Reticulocytes are produced in the bone marrow and then released into the bloodstream, where they mature into fully developed red blood cells between 1-2 days. Reticulocytosis often reflects the body’s response to conditions rather than an independent disease process and can arise from a variety of causes such as blood loss or anemia.
Reticulocytosis results from the body’s physiological response to an increased need for red blood cells. When red blood cells are destroyed or lost, tissues experience low oxygen levels causing the kidneys to release the hormone erythropoietin. Erythropoietin signals the bone marrow to accelerate the production of red blood cells through a process called erythropoiesis. As a result, more reticulocytes are released into the bloodstream. These immature cells continue to mature into fully developed red blood cells in circulation, restoring the red cell count and supporting oxygen delivery to tissues.[2]
Broad category of anemias where red blood cells are destroyed faster than they can be replaced, prompting the bone marrow to increase red blood cell production and the release of immature red blood cells into the bloodstream. Reticulocytosis provides strong suspicion of hemolysis when present along with many other markers like elevations in lactate dehydrogenase and unconjugated bilirubin or a decrease in haptoglobin.
In response to significant blood loss, either acute (e.g., trauma or surgery) or chronic (e.g., gastrointestinal bleeding), the bone marrow increases production to replace lost red blood cells. This results in an increased reticulocyte count, as new immature cells are released and make up a larger proportion of the blood volume.
During pregnancy, folate deficiency can cause megaloblastic anemia in the mother and poses a significant neurological developmental risk for the fetus. Upon initiation of maternal folate supplementation to prevent fetal abnormalities, reticulocytosis is expected after 3–4 days of treatment.
Reticulocytosis is typically diagnosed through a reticulocyte count, which measures the percentage or absolute number of reticulocytes in the blood. Common diagnostic tools for hematological disorders that may cause reticulocytosis include:
Reticulocyte Production Index (RPI)
Calculation that corrects for reticulocytes counts that may be misleadingly elevated due to the decrease in total red blood cells seen in anemia. Calculated as [%reticulocyte count x Patient Hct] / 45(normal Hct). This adjustment provides insight into whether reticulocyte production is adequate for the level of anemia.
Complete Blood Count (CBC): Provides a value for a variety of blood components, including red blood cells, hemoglobin, and hematocrit levels.
Common lab test in the work up of blood disorders that evaluates the size, shape, and maturity of red blood cells and reticulocytes by observing them under a microscope.This can help narrow down the etiology of the reticulocytosis.
The management of reticulocytosis involves treating the underlying cause rather than attempting to treat the high reticulocyte count itself.